our products
Contact phone

Velpanat®

Antivirals Velpanat (Generic) Generic drugs, marketed without brand names, contain the exact same active ingredients used in their brand-name counterparts, but cost significantly less. The drugs are required to meet US Food and Drug Administration (FDA) standards for safety, purity and effectiveness.
Velpanat

Natco Pharma has developed a brand new medicine with broad use for the treatment of hepatitis C called Velpanat. Sofosbuvir and velpatasvir are both components of this medication. Antiviral drugs such as sofosbuvir and velpatasvir stop the hepatitis C virus, often known as HCV, from replicating in your body. Additionally, Velpanat is utilized in the treatment of chronic hepatitis C in persons who have HCV genotypes 1, 2, 3, 4, 5, or 6.

BEST DEAL!

Save 20% with

Coupon "PKVCbYFj9G"

Generic Velpanat: A Comprehensive Overview

Introduction

Generic Velpanat is a combination antiviral medication used primarily in the treatment of chronic hepatitis C virus (HCV) infection. It is a generic version of the brand-name drug Epclusa, which is manufactured by Gilead Sciences. Generic Velpanat contains two active ingredients: Sofosbuvir (400 mg) and Velpatasvir (100 mg). These two components work synergistically to inhibit the replication of the hepatitis C virus, thereby reducing the viral load in the body and helping to achieve a sustained virologic response (SVR), which is considered a cure for hepatitis C.

Mechanism of Action

  1. Sofosbuvir: Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication. By incorporating itself into the viral RNA, Sofosbuvir acts as a chain terminator, effectively halting the replication process of the virus.

  2. Velpatasvir: Velpatasvir is an NS5A inhibitor, which means it targets the NS5A protein, a key component in the replication and assembly of the hepatitis C virus. By inhibiting this protein, Velpatasvir disrupts the viral life cycle, preventing the virus from multiplying and spreading within the body.

The combination of Sofosbuvir and Velpatasvir in Generic Velpanat provides a potent antiviral effect, making it effective against all six major genotypes of the hepatitis C virus. This pan-genotypic activity is one of the key advantages of Generic Velpanat, as it simplifies the treatment regimen and eliminates the need for genotype testing in many cases.

Indications

Generic Velpanat is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults. It is effective across all six major genotypes of HCV (genotypes 1, 2, 3, 4, 5, and 6). The medication is used in patients with or without compensated cirrhosis (liver scarring) and is also indicated for patients with decompensated cirrhosis when used in combination with ribavirin.

Dosage and Administration

The standard dosage of Generic Velpanat is one tablet taken orally once daily, with or without food. Each tablet contains 400 mg of Sofosbuvir and 100 mg of Velpatasvir. The duration of treatment typically ranges from 12 to 24 weeks, depending on the patient's HCV genotype, the presence of cirrhosis, and prior treatment history.

  • For patients without cirrhosis or with compensated cirrhosis: The recommended treatment duration is 12 weeks.

  • For patients with decompensated cirrhosis: Generic Velpanat is used in combination with ribavirin for 12 weeks.

It is crucial for patients to adhere to the prescribed dosage and treatment duration to maximize the effectiveness of the medication and reduce the risk of viral resistance.

Efficacy and Clinical Trials

Generic Velpanat has demonstrated high efficacy in clinical trials, with cure rates (sustained virologic response, SVR) exceeding 95% across all HCV genotypes. The ASTRAL trials, which were pivotal in the approval of the brand-name drug Epclusa, showed that the combination of Sofosbuvir and Velpatasvir was highly effective in achieving SVR12 (undetectable HCV RNA 12 weeks after completing treatment) in patients with HCV genotypes 1 through 6.

  • ASTRAL-1: This trial included patients with HCV genotypes 1, 2, 4, 5, and 6. The SVR12 rate was 99% for genotype 1, 100% for genotype 2, 100% for genotype 4, 97% for genotype 5, and 100% for genotype 6.

  • ASTRAL-2: Focused on patients with HCV genotype 2, the SVR12 rate was 99%.

  • ASTRAL-3: In patients with HCV genotype 3, the SVR12 rate was 95%.

  • ASTRAL-4: This trial included patients with decompensated cirrhosis (Child-Pugh class B). The SVR12 rate was 94% when Generic Velpanat was used in combination with ribavirin.

These results underscore the high efficacy of Generic Velpanat in treating chronic HCV infection across a broad spectrum of patient populations.

Safety and Side Effects

Generic Velpanat is generally well-tolerated, with most side effects being mild to moderate in severity. Common side effects include:

  • Headache

  • Fatigue

  • Nausea

  • Insomnia

  • Diarrhea

  • Weakness

Serious side effects are rare but may include:

  • Severe bradycardia (slow heart rate) when used with amiodarone (a heart medication)

  • Hepatitis B virus (HBV) reactivation in patients co-infected with HBV and HCV

  • Severe allergic reactions (rash, swelling, difficulty breathing)

Patients should be monitored for signs of HBV reactivation, especially those with a history of HBV infection. Additionally, Generic Velpanat should not be used in combination with certain medications, such as rifampin or St. John's wort, due to potential drug interactions that may reduce its effectiveness.

Contraindications

Generic Velpanat is contraindicated in patients who are hypersensitive to Sofosbuvir, Velpatasvir, or any of the excipients in the formulation. It is also contraindicated in patients taking certain medications that may interact adversely with Sofosbuvir or Velpatasvir, such as:

  • Rifampin (an antibiotic)

  • St. John's wort (a herbal supplement)

  • Certain anticonvulsants (e.g., carbamazepine, phenytoin)

Drug Interactions

Generic Velpanat has the potential to interact with a wide range of medications, which may alter its effectiveness or increase the risk of side effects. Some notable drug interactions include:

  • Amiodarone: Concurrent use with Generic Velpanat may lead to severe bradycardia. This combination should be avoided.

  • Antacids and H2-receptor antagonists: These may reduce the absorption of Velpatasvir. It is recommended to take Generic Velpanat 4 hours before or after taking antacids or H2-receptor antagonists.

  • Proton pump inhibitors (PPIs): PPIs may decrease the concentration of Velpatasvir. If PPIs are necessary, they should be taken at the same time as Generic Velpanat, with food.

  • HIV medications: Certain HIV medications, such as efavirenz, tenofovir disoproxil fumarate, and tipranavir/ritonavir, may interact with Generic Velpanat. Dose adjustments or alternative therapies may be required.

Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking before starting treatment with Generic Velpanat.

Special Populations

  1. Pregnancy and Breastfeeding: There is limited data on the use of Generic Velpanat in pregnant women. It should be used during pregnancy only if the potential benefits outweigh the risks. Breastfeeding is not recommended during treatment with Generic Velpanat, as it is unknown whether the drug is excreted in human milk.

  2. Pediatric Patients: The safety and efficacy of Generic Velpanat have not been established in children under the age of 18.

  3. Elderly Patients: No dose adjustment is required for elderly patients. However, older patients may be more susceptible to certain side effects, such as fatigue and weakness.

  4. Patients with Renal Impairment: No dose adjustment is required for patients with mild to moderate renal impairment. However, the safety and efficacy of Generic Velpanat have not been established in patients with severe renal impairment or end-stage renal disease requiring dialysis.

  5. Patients with Hepatic Impairment: Generic Velpanat can be used in patients with mild to moderate hepatic impairment without dose adjustment. In patients with decompensated cirrhosis, Generic Velpanat should be used in combination with ribavirin.

Cost and Accessibility

One of the significant advantages of Generic Velpanat is its cost-effectiveness compared to the brand-name drug Epclusa. The introduction of generic versions has made hepatitis C treatment more accessible to patients in low- and middle-income countries, where the prevalence of HCV is often high. Generic Velpanat is manufactured by several pharmaceutical companies, including Natco Pharma, Hetero Labs, and Mylan, among others. The availability of multiple generic versions has driven down the cost of treatment, making it more affordable for a broader population.

Conclusion

Generic Velpanat represents a significant advancement in the treatment of chronic hepatitis C virus infection. Its pan-genotypic efficacy, high cure rates, and relatively mild side effect profile make it a preferred choice for healthcare providers and patients alike. The availability of generic versions has further enhanced its accessibility, allowing more patients to benefit from this life-saving treatment. As with any medication, it is essential for patients to follow their healthcare provider's instructions carefully and to be aware of potential drug interactions and side effects. With proper use, Generic Velpanat offers hope for a cure to millions of people living with chronic hepatitis C worldwide.

What is sofosbuvir and velpatasvir? Antiviral drugs such as sofosbuvir and velpatasvir stop the hepatitis C virus, often known as HCV, from replicating in your body. A combination medication called sofosbuvir and velpatasvir is employed in the treatment of chronic hepatitis C in individuals who have HCV genotype 1, 2, 3, 4, 5, or 6. In patients who also have severe cirrhosis, this treatment is typically administered in conjunction with ribavirin, which is also an antiviral medication. There are more applications for sofosbuvir and velpatasvir that are not included in this patient information leaflet. What is the most essential information I need to be aware of with the combination of sofosbuvir and velpatasvir? It is possible to treat hepatitis C with a combination of sofosbuvir and velpatasvir with ribavirin. Ribavirin exposes an unborn child to a risk of birth abnormalities as well as possible death. If you are pregnant or if your sexual partner is pregnant, you should not take ribavirin. The same goes for men whose partners are pregnant. When taking both of these medications simultaneously, as well as for at least six months after treatment has finished, you should avoid pregnancy by using an effective method of birth control. You should go over each medicine in your combination therapy and read the medication guide or patient instructions that come with it. Do not make any adjustments to your dosage or drug regimen without first consulting your doctor. Sofosbuvir and velpatasvir pose a risk of reactivating or exacerbating hepatitis B in patients who have previously been infected with the virus. In order to monitor your liver function accurately, you will require periodic blood tests. What questions should I ask my doctor or other healthcare professional before starting treatment with sofosbuvir and velpatasvir? If you have ever had an adverse reaction to sofosbuvir or velpatasvir, you should not use this drug. If you have any of the following conditions, you should let your doctor know before using this medication: a previous diagnosis of hepatitis B; if you suffer from renal disease or are already receiving dialysis; difficulties with the liver that aren't caused by hepatitis; Human immunodeficiency virus, also known as HIV; or If you have recently taken the medication called amiodarone to treat an irregular heartbeat (Cordarone, Pacerone). It is unknown at this time whether or not the combination of sofosbuvir and velpatasvir would cause damage to an unborn child. Inform your physician if you are pregnant or if you want to become pregnant in the near future. This treatment is often used in conjunction with ribavirin in some cases. Ribavirin exposes an unborn child to a risk of birth abnormalities as well as possible death. Before taking both of these drugs at the same time, as well as at regular intervals while you are being treated, you should be sure that a pregnancy test comes out negative. If you are a woman and you get pregnant, you should not use sofosbuvir and velpatasvir in combination with ribavirin. If you are a guy and your sexual partner is pregnant, you should avoid using this medicine combination at all costs. If a man is the father of an unborn kid while he is taking ribavirin, there is a possibility that the unborn child will be injured. While taking these drugs together, one or both sexual partners should use an effective method of birth control to reduce the risk of becoming pregnant. When your treatment is over, you should continue taking this method of birth control for at least another six months. Notify your healthcare provider as soon as possible if you become pregnant when either you or the potential father is taking sofosbuvir and velpatasvir in combination with ribavirin. It is unknown whether sofosbuvir and velpatasvir move into breast milk or whether it might cause damage to a baby who is being breastfed. When you are taking this medication, you should not breastfeed your child. What is the correct way for me to take sofosbuvir and velpatasvir? Your physician will examine your blood to determine whether or not you have any problems that would prevent you from utilizing this medication in a secure manner if you did so. The combination of sofosbuvir and velpatasvir is typically administered once daily for a period of 12 weeks. Always make sure to follow all of the instructions on the label of your medication. Do not use this medication in greater or lower doses than indicated, nor for a longer period of time than specified. You can take this medication either with or without food. Either way is OK. In order to monitor your liver function accurately, you will require periodic blood tests. Combinations of medications are frequently used in the treatment of hepatitis C. Always follow your physician's instructions while using any medicine. You should go through and read all of the patient information, prescription guidelines, and instruction sheets that have been sent to you. Do not make any adjustments to your dosage or drug regimen without first consulting your doctor. Any individual who has chronic hepatitis C should continue to receive treatment from a medical professional. It is not recommended that you quit taking sofobuvir and velpatasvir all of a sudden. Your illness may become more difficult to manage with hepatitis C antiviral medication if you suddenly stop using the drug. Sofosbuvir and velpatasvir pose a risk of reactivating or exacerbating hepatitis B in patients who have previously been infected with the virus. Over the course of therapy, as well as for many months after you have stopped taking this medication, you will be required to have tests done to evaluate your liver's function. Keep this medication in its original container at room temperature, away from moisture and heat, and out of the reach of children. What can I expect if I forget to take a dose? When you realize you missed a dosage, take it as soon as you can. If it is almost time for your next scheduled dosage, you should skip the dose that you missed. It is not necessary to take additional medication in order to make up for a missed dosage. What should I try to steer clear of while I'm on the combination of sofosbuvir and velpatasvir? If you also take omeprazole (Prilosec) or an antacid, wait at least four hours after taking your dosage of sofosbuvir and velpatasvir before taking another dose of either of those medications (with food). Even if you take this treatment regularly, you will not be protected from transmitting hepatitis C to other individuals. Do not engage in unprotected sexual activity, nor should you share utensils such as razors or toothbrushes. Have a conversation with your healthcare provider about effective methods of preventing the spread of HCV through sexual activity. It is never safe, even for a healthy individual, to share needles that have been used for drugs or medicine. The negative consequences of sofosbuvir and velpatasvir You should seek immediate medical attention if you have the following symptoms of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or neck. You should see your physician as soon as possible if you have: a rhythm that is sluggish; a shallow or labored breathing pattern; or a low number of red blood cells can cause symptoms such as pale complexion, weakness, fast heart rate, and difficulty focusing. If you are also taking amiodarone, you should seek immediate medical attention if you have symptoms such as feeling weak, weary, or lightheaded; chest discomfort; shortness of breath; disorientation; or difficulties with your memory. The following are examples of common adverse effects: headache; fatigued sensation; nausea, diarrhea; or sleep troubles (insomnia). Which other medications might potentially interact with sofosbuvir and velpatasvir? It is possible that using certain drugs at the same time might have adverse effects. Some medications have the potential to alter the blood levels of other medications that you take, which may result in an increase in adverse effects or a reduction in the efficacy of the prescriptions. Other medications, such as prescription and over-the-counter treatments, vitamins, and herbal remedies, might potentially have an adverse reaction when used with sofosbuvir and velpatasvir. Talk to your primary care physician about any and all medications you are currently taking, as well as any medications you decide to start or stop taking.

Testimonials

high quality medications

Free discreet shipping

Secure online transactions

Money-back guarantee

Fast worldwide delivery

By staying on our site you automatically agree with the storage and processing of your personal data, in accordance with our Privacy Policy.